DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. The company's lead product candidate, DM199, is a recombinant human tissue kallikrein-1 protein being studied for acute ischemic stroke and chronic kidney disease. DiaMedica focuses on leveraging the therapeutic properties of the kallikrein-kinin system. The company conducts clinical trials and preclinical research while seeking regulatory approval pathways for its drug candidates.